Restoring Confidence in the World Anti-Doping Agency Act of 2025
Impact
If passed, HB 693 would significantly modify the relationship between the U.S. and WADA by emphasizing the need for credible governance that represents American interests. The Office of National Drug Control Policy would be empowered to assess and report on WADA's compliance with governance reforms, including conflict-of-interest policies. This legislative change could alter the dynamics of international sports governance, fostering a more participatory model that includes independent athletes in decision-making processes, thereby promoting integrity in anti-doping efforts.
Summary
House Bill 693, titled the 'Restoring Confidence in the World Anti-Doping Agency Act of 2025', aims to amend the Office of National Drug Control Policy Reauthorization Act of 2006. The bill primarily focuses on enhancing the governance and accountability of the World Anti-Doping Agency (WADA), specifically addressing representation and decision-making roles for independent athletes from the United States and other democratic nations. Through this act, the Office of National Drug Control Policy will be tasked with ensuring that WADA adopts governance reforms to promote fairness and transparency in its operations, which is crucial in the fight against doping in sports.
Contention
Among the notable points of contention surrounding the bill is the debate on the effectiveness of current governance structures within WADA. Critics may argue about the feasibility of requiring such extensive reforms and whether the proposed measures will adequately address the systemic issues related to doping. Furthermore, there could be concerns regarding the implications this bill may have on funding and resources allocated to anti-doping efforts, as the authority to withhold dues based on WADA’s compliance could become a contentious issue within the broader context of international sports funding and governance.
Restoring Trade Fairness ActThis bill establishes various trade measures related to China, including by revoking China's permanent normal trade relations (PNTR) status and increasing the rates of duty (i.e., tariffs) on Chinese imported goods. The bill prohibits imported goods originating from North Korea, China, Russia, or Iran from receiving de minimis treatment. (Current law allows for U.S. imports under a de minimis threshold of $800 per shipment to enter free of tariffs, fees, and taxes.)Specifically, the bill revokes China's PNTR status. Currently, China's PNTR status allows for Chinese goods to have duty rates set forth in column 1 of the Harmonized Tariff Schedule of the United States (HTS). With the removal of China's PNTR status, the bill generally sets the applicable duty rates on imported Chinese goods at the higher rates listed in column 2 of the HTS, with exceptions.The bill establishes a minimum duty rate of 35% for all Chinese goods, which requires column 2 rates to be at least 35%. However, the bill establishes a minimum duty rate of 100% for a list of specified goods (e.g., various minerals, certain vaccines and drugs, and certain defense-related articles). Duty rates are phased in over five years and adjusted annually for inflation.The bill alsoauthorizes the President to take additional actions related to trade with China, requires merchandise imported from China to be appraised based on U.S. value, and establishes a trust fund to compensate U.S. producers for lost revenue resulting from retaliatory actions by China.